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is essential that the medical profession play a central role in
itically evaluating the evidence related to drugs, devices,
d procedures for the detection, management, or prevention
disease. Properly applied, rigorous, expert analysis of the
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d reduce costs of care by focusing resources on the most
fective strategies. One important use of such data is the
oduction of clinical practice guidelines which, in turn, can
ovide a foundation for a variety of other applications such
performance measures, appropriate use criteria, clinical
cision support tools, and quality improvement tools.
The American College of Cardiology Foundation (ACCF)
d the American Heart Association (AHA) have jointly en-
ged in the production of guidelines in the area of cardiovas-
lar disease since 1980. The ACCF/AHA Task Force on
actice Guidelines is charged with developing, updating, and
vising practice guidelines for cardiovascular diseases and
ocedures, and the Task Force directs and oversees this effort.
riting committees are charged with assessing the evidence as
independent group of authors to develop, update, or revise
commendations for clinical practice.
Experts in the subject under consideration have been selected
om both organizations to examine subject-specific data and
rite guidelines in partnership with representatives from other
edical practitioner and specialty groups. Writing committees
e specifically charged to perform a formal literature review,
eigh the strength of evidence for or against particular treat-
ents or procedures, and include estimates of expected health
tcomes where data exist. Patient-specific modifiers, comor-
dities, and issues of patient preference that may influence the
oice of tests or therapies are considered. When available,
formation from studies on cost is considered, but data on
ficacy and clinical outcomes constitute the primary basis for
commendations in these guidelines.
The ACCF/AHA Task Force on Practice Guidelines makes
ery effort to avoid actual, potential, or perceived conflicts
interest that may arise as a result of industry relationships
personal interests among the writing committee. Specifi-
lly, all members of the writing committee, as well as peer
viewers of the document, are asked to disclose all current
lationships and those 24 months prior to initiation of the
riting effort that may be perceived as relevant. All guideline
commendations require a confidential vote by the writing
mmittee and must be approved by a consensus of the
embers voting. Members who were recused from voting are
ted on the title page of this document. Members must
cuse themselves from voting on any recommendation
here their relationships with industry (RWI) and other
tities apply. If a writing committee member develops a new
lationship with industry during his/her tenure, he/she is
quired to notify guideline staff in writing. These statements
e reviewed by the Task Force on Practice Guidelines and all
embers during each conference call and/or meeting of the
riting committee, updated as changes occur, and ultimately
blished as an appendix to the document. For detailed
formation regarding guideline policies and procedures,
ease refer to the methodology manual for ACCF/AHA
uideline Writing Committees (1). RWI and other entities
rtinent to this guideline for authors and peer reviewers are
sclosed in Appendixes 1 and 2, respectively. Disclosure
formation for the ACCF/AHA Task Force on Practice
uidelines is also available online at http://www.acc.org/
out/overview/ClinicalDocumentsTaskForces.cfm. giThese practice guidelines are intended to assist healthcare
oviders in clinical decision making by describing a range of
nerally acceptable approaches for diagnosis, management,
d prevention of specific diseases or conditions. Clinicians
ould consider the quality and availability of expertise in the
ea where care is provided. These guidelines attempt to
fine practices that meet the needs of most patients in most
rcumstances. The recommendations reflect a consensus
ter a thorough review of the available current scientific
idence and are intended to improve patient care. The Task
rce recognizes that situations arise where additional data
e needed to better inform patient care; these areas will be
entified within each respective guideline when appropriate.
Patient adherence to prescribed and agreed upon medical
gimens and lifestyles is an important aspect of treatment.
escribed courses of treatment in accordance with these
commendations are effective only if they are followed.
ecause lack of patient understanding and adherence may
versely affect outcomes, physicians and other healthcare
oviders should make every effort to engage the patient’s
tive participation in prescribed medical regimens and life-
yles.
If these guidelines are used as the basis for regulatory or
yer decisions, the goal should be improvement in quality of
re and aligned with the patient’s best interest. The ultimate
dgment regarding care of a particular patient must be made
the healthcare provider and the patient in light of all of the
rcumstances presented by that patient. Consequently, there
e circumstances in which deviations from these guidelines
e appropriate.
The guidelines will be reviewed annually by the ACCF/
HA Task Force on Practice Guidelines and considered
rrent unless they are updated, revised, or withdrawn from
stribution. The full-text guidelines are e-published in the
pril 6, 2010, issues of the Journal of the American College
Cardiology and Circulation (1a).
Alice K. Jacobs, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Practice Guidelines
Sidney C. Smith, Jr, MD, FACC, FAHA
Immediate Past Chair, ACCF/AHA Task Force on
Practice Guidelines
. Introduction
.1. Methodology and Evidence Review
he writing committee conducted a comprehensive search of
e medical and scientific literature through the use of
bMed/MEDLINE. Searches were limited to publications
ritten in the English language. Compiled reports were
viewed and additional articles were provided by committee
embers. Specifically targeted searches were conducted on
e following subtopics: acute aortic dissection, ankylosing
ondylitis, aortic dissection and litigation, aortic neoplasm,
rtic tumors, Behçet disease, bicuspid aortic valve, calcified
rta, chronic dissection, coarctation of the aorta, D-dimer,
ssecting aneurysm, Ehlers-Danlos syndrome, endovascular
d aortic aneurysms, medial degeneration, porcelain aorta,
ant cell arteritis, imaging and thoracic aortic disease,
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ndrome, Marfan syndrome, Noonan syndrome, penetrating
rtic ulcer, polycystic kidney disease, thoracic and aortic
eurysms, thoracic aortic disease and patient care, thoracic
rtic disease and surgery, thoracic aorta and Kawasaki
sease, Takayasu arteritis, thoracoabdominal and aorta or
rtic disease, and Turner syndrome. More than 850 refer-
ces were reviewed, with 830 used as the primary evidence
se for the final guideline. The ACCF/AHA Task Force on
actice Guidelines methodology processes were followed to
rite the text and recommendations. In general, published
anuscripts appearing in journals listed in Index Medicus
ere used as the evidence base. Published abstracts were used
ly for emerging information but were not used in the
rmulation of recommendations.
The committee reviewed and ranked evidence supporting
rrent recommendations with the weight of evidence ranked
Level A if the data were derived from multiple randomized
inical trials or meta-analyses. The committee ranked avail-
le evidence as Level B when data were derived from a
ngle randomized trial or nonrandomized studies. Evidence
as ranked as Level C when the primary source of the
commendation was consensus opinion, case studies, or
andard of care. In the narrative portions of these guidelines,
idence is generally presented in chronologic order of
velopment. Studies are identified as observational, retro-
ective, prospective, or randomized. For certain conditions
r which inadequate data are available, recommendations are
sed on expert consensus and clinical experience and are
nked as Level C. An analogous example is the use of
nicillin for pneumococcal pneumonia, where there are no
ndomized trials and treatment is based on clinical experi-
ce. When recommendations at Level C are supported by
storical clinical data, appropriate references (including
inical reviews) are cited if available. For issues where
arse data are available, a survey of current practice among
e clinicians on the writing committee formed the basis for
evel C recommendations and no references are cited. The
hema for classification of recommendations and level of
idence is summarized in Table 1, which also illustrates how
e grading system provides an estimate of the size of the
eatment effect and an estimate of the certainty of the
eatment effect.
To provide clinicians with a comprehensive set of data,
henever possible, the exact event rates in various treatment
ms of clinical trials are presented to permit calculation of
e absolute risk difference (ARD), number needed to harm
NH); the relative treatment effects are described either as
ds ratio (OR), relative risk (RR), or hazard ratio (HR)
pending on the format in the original publication. Along
ith all other point statistics, confidence intervals (CIs) for
ose statistics are added when available.
The writing committee recognized that the evidence base
r this guideline is less robust in terms of randomized
inical trials than prior ACCF/AHA guidelines, particularly
ose focused on coronary artery disease (CAD) and heart
ilure. As the reader will discern, much of the evidence base
r this topic consists of cohort studies and retrospective
views, which largely emanate from centers with a special- Aed interest in specific types of thoracic aortic disease. The
riting committee attempted to focus on providing the
actitioner with recommendations for evaluation and treat-
ent wherever possible and where controversy exists, iden-
ed as such in the text.
The writing committee acknowledges the expertise of the
ghly experienced and effective practice guidelines staff of
e ACCF and AHA. The writing committee chair also
knowledges the commitment and dedication of the diverse
riting committee members who were able to put aside issues
specialty “turf” and focus on providing the medical
mmunity with a guideline aimed at optimal patient care.
.2. Organization of the Writing Committee
he guideline was written by a committee comprised of
perts in cardiovascular medicine, surgery, radiology, and
rsing. For many of the previous ACCF/AHA practice
idelines, writing expertise has been available within these 2
ganizations. Because of the broad scope and diversity of
oracic aortic diseases, as well as the specialists who treat
ch patients, the ACCF and AHA sought greater involve-
ent from many specialty organizations. Most, but not all,
ecialty organizations that represent the major stakeholders
ring for patients with thoracic aortic diseases provided
riting committee members and financial support of the
oject, and they are recognized as marquee level partners
ith the ACCF and AHA. These organizations included the
merican Association for Thoracic Surgery (AATS), Amer-
an College of Radiology (ACR), American Stroke Associ-
ion (ASA), Society of Cardiovascular Anesthesiologists
CA), Society for Cardiovascular Angiography and Inter-
ntions (SCAI), Society of Interventional Radiology (SIR),
ciety of Thoracic Surgeons (STS), and Society for Vascu-
r Medicine (SVM). The American College of Emergency
ysicians (ACEP) and the American College of Physicians
CP) were also represented on the writing committee.
here additional expertise was needed, the scientific councils
the AHA were contacted for writing committee represen-
tives. Representation was provided or facilitated by the
ouncils on Cardiovascular Nursing, Cardiovascular Surgery
d Anesthesia, Cardiovascular Radiology and Intervention,
d Clinical Cardiology, Council for High Blood Pressure
esearch, and Stroke Council.
.3. Document Review and Approval
his document was reviewed by 3 outside reviewers nomi-
ted by the ACCF and 2 outside reviewers nominated by the
HA, as well as 1 or 2 reviewers from each of the following
ganizations: the AATS, ACP, ACEP, ACR, ASA, SCA,
AI, SIR, STS, and the SVM. It was also reviewed by 6
dividual content reviewers—2 content reviewers from the
CCF Catheterization Committee and 1 content reviewer
om the ACCF Interventional Council. All reviewer RWI
formation was collected and distributed to the writing
mmittee and is published in this document (see Appendix 2).
This document was approved for publication by the gov-
ning bodies of the ACCF and the AHA; and the AATS,
CR, ASA, SCA, SCAI, SIR, STS, and SVM and was
en
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aging.
.4. Scope of the Guideline
he term thoracic aortic disease encompasses a broad range
degenerative, structural, acquired, genetic-based, and trau-
atic disease states and presentations. According to the
enters for Disease Control and Prevention death certificate
ta, diseases of the aorta and its branches account for 43 000
47 000 deaths annually in the United States (2). The precise
mber of deaths attributable to thoracic aortic diseases is
clear. However, autopsy studies suggest that the presenta-
n of thoracic aortic disease is often death due to aortic
ssection (AoD) and rupture, and these deaths account for
ice as many deaths as attributed to ruptured abdominal
ble 1. Applying Classification of Recommendations and Level
*Data available from clinical trials or registries about the usefulness/efficacy
yocardial infarction, history of heart failure, and prior aspirin use. A recommend
any important clinical questions addressed in the guidelines do not lend them
a very clear clinical consensus that a particular test or therapy is useful or
†In 2003, the ACCF/AHA Task Force on Practice Guidelines developed a
commendations have been written in full sentences that express a complete
e rest of the document (including headings above sets of recommendations),
rease readers’ comprehension of the guidelines and will allow queries at thertic aneurysms (AAAs) (3). The diagnosis of acute thoracic paoD or rupture is often difficult and delayed, and errors in
agnosis may account for deaths otherwise attributed to
rdiac arrhythmia, myocardial infarction (MI), pulmonary
bolism, or mesenteric ischemia.
Most patients with significant thoracic aortic disease
ill be directed to specialized practitioners and institu-
ons. However, the importance of early recognition and
ompt treatment and/or referral for a variety of thoracic
rtic diseases by all healthcare professionals provides the
tionale for this document. This guideline will provide the
actitioner with a sufficient description of background
formation, diagnostic modalities, and treatment strate-
es so that appropriate care of these patients can be
cilitated and better understood. The goal of this guideline
to improve the health outcomes and quality of life for all
ence
rent subpopulations, such as sex, age, history of diabetes, history of prior
th Level of Evidence B or C does not imply that the recommendation is weak.
o clinical trials. Even though randomized trials are not available, there may
.
suggested phrases to use when writing recommendations. All guideline
, such that a recommendation, even if separated and presented apart from
still convey the full intent of the recommendation. It is hoped that this will
ual recommendation level.of Evid
in diffe
ation wi
selves t
effective
list of
thought
wouldtients with thoracic aortic disease.
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2010 Guidelines on TAD: Executive Summary April 6, 2010:1509–44This guideline includes diseases involving any or all parts
the thoracic aorta with the exception of aortic valve
seases (4) and includes the abdominal aorta when contigu-
s thoracic aortic diseases are present. Specific disease states
e described in the following sections and the reader is
ferred to the glossary of terminology in Section 1.5 for
breviations used throughout the guideline.
4.1. Critical Issues
s the writing committee developed this guideline, several
itical issues emerged:
Thoracic aortic diseases are usually asymptomatic and not
easily detectable until an acute and often catastrophic
complication occurs. Imaging of the thoracic aorta with
computed tomographic imaging (CT), magnetic resonance
imaging (MR), or in some cases, echocardiographic exam-
ination is the only method to detect thoracic aortic diseases
and determine risk for future complications.
Radiologic imaging technologies have improved in terms
of accuracy of detection of thoracic aortic disease. How-
ever, as the use of these technologies has increased, so also
has the potential risk associated with repeated radiation
exposure, as well as contrast medium–related toxicity.
Whether these technologies should be used repeatedly as a
widespread screening tool is discussed in the full-text
document. In addition, the writing committee formulated
recommendations on a standard reporting format for tho-
racic aortic findings as discussed in Section 4.
Imaging for asymptomatic patients at high risk based on
history or associated diseases is expensive and not always
covered by payers.
For many thoracic aortic diseases, results of treatment for
stable, often asymptomatic, but high-risk conditions are far
better than the results of treatment required for acute and
often catastrophic disease presentations. Thus, the identi-
fication and treatment of patients at risk for acute and
catastrophic disease presentations (e.g., thoracic AoD and
thoracic aneurysm rupture) prior to such an occurrence are
paramount to eliminating the high morbidity and mortality
associated with acute presentations.
A subset of patients with acute AoD are subject to missed
or delayed detection of this catastrophic disease state.
Many present with atypical symptoms and findings, mak-
ing diagnosis even more difficult. This issue has come
under greater medical-legal scrutiny, and specific cases
have been widely discussed in the public domain. Wide-
spread awareness of the varied and complex nature of
thoracic aortic disease presentations has been lacking,
especially for acute AoD. Risk factors and clinical presen-
tation clues are noted in Section 9. The collaboration and
cosponsorship of multiple medical specialties in the writ-
ing of this guideline will provide unique opportunities for
widespread dissemination of knowledge to raise the level
of awareness among all medical specialties.
There is rapidly accumulating evidence that genetic alter-
ations or mutations predispose some individuals to aortic
diseases. Therefore, identification of the genetic alterations
leading to these aortic diseases has the potential for early
identification of individuals at risk. In addition, biochem- orical abnormalities involved in the progression of aortic
disease are being identified through studies of patients’
aortic samples and animal models of the disease (5,6). The
biochemical alterations identified in the aortic tissue have
the potential to serve as biomarkers for aortic disease.
Understanding the molecular pathogenesis may lead to
targeted therapy to prevent aortic disease. Medical and
gene-based treatments are beginning to show promise for
reducing or delaying catastrophic complications of tho-
racic aortic diseases.
.5. Glossary of Terms and Abbreviations
sed Throughout the Guideline
neurysm (or true aneurysm): a permanent localized dila-
tation of an artery, having at least a 50% increase in
diameter compared to the expected normal diameter of the
artery in question. Although all 3 layers (intima, media,
and adventitia) may be present, the intima and media in
large aneurysms may be so attenuated that in some
sections of the wall they are undetectable.
seudoaneurysm (or false aneurysm): contains blood re-
sulting from disruption of the arterial wall with extrava-
sation of blood contained by periarterial connective tissue
and not by the arterial wall layers. Such an extravascular
hematoma that freely communicates with the intravascular
space is also known as a pulsating hematoma (7–9).
ctasia: arterial dilatation less than 150% of normal arterial
diameter.
rteriomegaly: diffuse arterial dilatation involving several ar-
terial segments with an increase in diameter greater than 50%
by comparison to the expected normal arterial diameter.
horacoabdominal aneurysm (TAA): aneurysm involving
the thoracic and abdominal aorta.
bdominal aortic aneurysm (AAA): aneurysm involving
the infradiaphragmatic abdominal aorta.
ortic dissection (AoD): disruption of the media layer of the
aorta with bleeding within and along the wall of the aorta.
Dissection may, and often does, occur without an aneu-
rysm being present. An aneurysm may, and often does,
occur without dissection. The term dissecting aortic aneu-
rysm is often used incorrectly and should be reserved only
for those cases where a dissection occurs in an aneurysmal
aorta.
. The Thoracic Aorta
he thoracic aorta is divided into 4 parts: the aortic root
hich includes the aortic valve annulus, the aortic valve
sps, and the sinuses of Valsalva); the ascending aorta
hich includes the tubular portion of the ascending aorta
ginning at the sinotubular junction and extending to the
achiocephalic artery origin); the aortic arch (which begins
the origin of the brachiocephalic artery, and is the origin of
e head and neck arteries, coursing in front of the trachea and
the left of the esophagus and the trachea); and the
scending aorta (which begins at the isthmus between the
igin of the left subclavian artery and the ligamentum
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en through the diaphragm into the abdomen) (see Figure 1).
The normal human adult aortic wall is composed of 3
yers, listed from the blood flow surface outward:
tima: Endothelial layer on a basement membrane with
minimal ground substance and connective tissue.
edia: Bounded by an internal elastic lamina, a fenestrated
sheet of elastic fibers; layers of elastic fibers arranged
concentrically with interposed smooth muscle cells;
bounded by an external elastic lamina, another fenestrated
sheet of elastic fibers.
dventitia: A resilient layer of collagen containing the vasa
vasorum and nerves. Some of the vasa vasorum can
penetrate into the outer third of the media.
. Thoracic Aortic Histopathology
.1. Atherosclerosis
1995 consensus document from the AHA defines the types
d histological classes of atherosclerosis (10) (Figure 2).
.2. Aneurysms and Dissections
ortic aneurysm histopathology, more accurately termed
edial degeneration, is characterized by disruption and loss
elastic fibers and increased deposition of proteoglycans.
gure 1. Normal anatomy of the thoracoabdominal aorta with
andard anatomic landmarks for reporting aortic diameter as
strated on a volume-rendered CT image of the thoracic aorta.
T indicates computed tomographic imaging. Anatomic loca-
ns: 1, Aortic sinuses of Valsalva; 2, Sinotubular junction; 3,
id ascending aorta (midpoint in length between Nos. 2 and 4);
Proximal aortic arch (aorta at the origin of the innominate ar-
ry); 5, Mid aortic arch (between left common carotid and sub-
avian arteries); 6, Proximal descending thoracic aorta (begins
the isthmus, approximately 2 cm distal to left subclavian ar-
ry); 7, Mid descending aorta (midpoint in length between Nos.
and 8); 8, Aorta at diaphragm (2 cm above the celiac axis ori-
n); 9, Abdominal aorta at the celiac axis origin. CT indicates
mputed tomographic imaging.ypically, there are areas of loss of smooth muscle cells in thertic media, but whether there is a total loss of smooth
uscle cells in the aortic wall is not clear. Recent literature
pports the presence of inflammatory cell infiltration in this
sease (11,12). Aortic pathology associated with myosin
avy chain 11, smooth muscle (MYH11) and actin, alpha 2,
ooth muscle aorta (ACTA2) mutations leading to ascending
rtic aneurysms demonstrates a hyperplastic response by
ooth muscle cells in the aortic media. The aortic media in
eurysm tissue taken from patients harboring mutations in
ese genes demonstrated focal hyperplasia associated with
ooth muscle cells that were remarkable for a lack of
ructured orientation parallel to the lumen of the aorta, but
stead, the smooth muscle cells were oriented randomly with
spect to one another (13,14).
Increased immunostaining for a subset of matrix metallo-
oteinases (MMPs) has been described in the media of
oracic aortic aneurysms, particularly MMP-2 and MMP-9
5–18). Immunostaining of aortic media from patients with
arfan syndrome has demonstrated increases of MMP-2 and
MP-9, which was associated with smooth muscle cells at
e borders of areas of medial degeneration and on the surface
disrupted elastic fibers. Elevated MMP-2 and MMP-9
munostaining has been demonstrated in ascending aneu-
sms from patients with either tricuspid or bicuspid aortic
lves (16,18) and inconsistently in ascending aortic tissue
om patients with tricuspid aortic valves (17). These 2
MPs are known to have elastolytic activity. Variable
pression of MMPs and tissue inhibitors of MMPs has also
en demonstrated in aortic tissue of patients with Marfan
ndrome versus patients without Marfan syndrome (19).
lthough accumulation of proteoglycans in the aortic media
another consistent finding in thoracic aortic aneurysms, no
udies have determined why this accumulation occurs or
hether these are causative in nature.
.3. Vasculitis and Inflammatory Diseases
iant cell arteritis and Takayasu arteritis share important
atures (19a) with T-cell clonal expansion suggesting an
tigenic response. An adventitial inflammatory response is
arked by augmented cytokine and MMP production causing
anuloma formation, which causes vessel destruction (19b).
ehçet disease affects both arteries and veins of all sizes.
. Recommendations for Aortic Imaging
echniques to Determine the Presence
nd Progression of Thoracic Aortic
isease
ASS I
Measurements of aortic diameter should be taken at reproduc-
ible anatomic landmarks, perpendicular to the axis of blood
flow, and reported in a clear and consistent format (see Table
2). (Level of Evidence: C)
For measurements taken by computed tomographic imaging or
magnetic resonance imaging, the external diameter should be
measured perpendicular to the axis of blood flow. For aortic
root measurements, the widest diameter, typically at the
mid-sinus level, should be used. (Level of Evidence: C)
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diameter should be measured perpendicular to the axis of
blood flow. For aortic root measurements the widest diameter,
typically at the mid-sinus level, should be used. (Level of
Evidence: C)
Abnormalities of aortic morphology should be recognized and
reported separately even when aortic diameters are within
normal limits. (Level of Evidence: C)
The finding of aortic dissection, aneurysm, traumatic injury
and/or aortic rupture should be immediately communicated to
the referring physician. (Level of Evidence: C)
ble 2. Essential Elements of Aortic Imaging Reports
The location at which the aorta is abnormal.
The maximum diameter of any dilatation, measured from the external
wall of the aorta, perpendicular to the axis of flow, and the length of the
aorta that is abnormal.
For patients with presumed or documented genetic syndromes at risk for
aortic root disease measurements of aortic valve, sinuses of Valsalva,
sinotubular junction, and ascending aorta.
The presence of internal filling defects consistent with thrombus or
atheroma.
The presence of IMH, PAU, and calcification.
Extension of aortic abnormality into branch vessels, including dissection
and aneurysm, and secondary evidence of end-organ injury (e.g., renal
or bowel hypoperfusion.
Evidence of aortic rupture, including periaortic and mediastinal
hematoma, pericardial and pleural fluid, and contrast extravasation from
the aortic lumen.
When a prior examination is available, direct image to image comparison
to determine if there has been any increase in diameter.
IMH indicates intramural hematoma; and PAU, penetrating atherosclerotic
er. apTechniques to minimize episodic and cumulative radiation
exposure should be utilized whenever possible. (20,21) (Level
of Evidence: B)
ASS IIa
If clinical information is available, it can be useful to relate
aortic diameter to the patient’s age and body size (see Tables
3 and 4). (Level of Evidence: C)
efinitive identification or exclusion of thoracic aortic dis-
se or one of its anatomic variants requires dedicated aortic
aging. Selection of the most appropriate imaging study
ay depend on patient related factors (i.e., hemodynamic
ability, renal function, contrast allergy) and institutional
pabilities (i.e., rapid availability of individual imaging
odalities, state of the technology, and imaging specialist
pertise). Consideration should be given to patients with
Figure 2. Atherosclerotic lesions. Flow dia-
gram in center column indicates pathways
in evolution and progression of human ath-
erosclerotic lesions. Roman numerals indi-
cate histologically characteristic types of
lesions defined at the left of the flow dia-
gram. The direction of the arrows indicates
the sequence in which characteristic mor-
phologies may change. From Type I to
Type IV, changes in lesion morphology oc-
cur primarily because of increasing accu-
mulation of lipid. The loop between Types
V and VI illustrates how lesions increase in
thickness when thrombotic deposits form
on their surfaces. Thrombotic deposits may
form repeatedly over varied time spans in
the same location and may be the principal
mechanism for gradual occlusion of medi-
um-sized arteries. Adapted from Stary et al.
(10).
ble 3. Normal Adult Thoracic Aortic Diameters
oracic Aorta
Range of
Reported
Mean (cm)
Reported
SD (cm)
Assessment
Method
ot (female) 3.50 to 3.72 0.38 CT
ot (male) 3.63 to 3.91 0.38 CT
cending (female, male) 2.86 NA CXR
id-descending (female) 2.45 to 2.64 0.31 CT
id-descending (male) 2.39 to 2.98 0.31 CT
aphragmatic (female) 2.40 to 2.44 0.32 CT
aphragmatic (male) 2.43 to 2.69 0.27 to 0.40 CT,
arteriography
CT indicates computed tomographic imaging; CXR, chest x-ray; and NA, not
plicable. Reprinted with permission from Johnston et al. (27).
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April 6, 2010:1509–44 2010 Guidelines on TAD: Executive Summaryrderline abnormal renal function (serum creatinine greater
an 1.8 to 2.0 mg/dL)—specifically, the tradeoffs between
e use of iodinated intravenous contrast for CT and the
ssibility of contrast-induced nephropathy, and gadolinium
ents used with MR and the risk of nephrogenic systemic
rosis (22).
Radiation exposure should be minimized (21,23–26). The
sk of radiation-induced malignancy is the greatest in neo-
tes, children, and young adults (21). Generally, above the
e of 30 to 35 years, the probability of radiation-induced
alignancy decreases substantially (20,21). For patients who
quire repeated imaging to follow an aortic abnormality, MR
ay be preferred to CT. MR may require sedation due to
nger examination times and tendency for claustrophobia.
CT as opposed to echocardiography can best identify
oracic aortic disease, as well as other disease processes that
n mimic aortic disease, including pulmonary embolism,
ricardial disease, and hiatal hernia. After intervention or
en surgery, CT is preferred to detect asymptomatic post-
ocedural leaks or pseudoaneurysms because of the presence
metallic closure devices and clips.
CT and MR measure external aortic diameter, whereas
hocardiography measures internal aortic diameter. Lumen
ze may not accurately reflect external diameter due to
traluminal clot, wall inflammation, or AoD. A recent
finement in the CT measurement of aortic size examines the
ssel size using a centerline of flow, which reduces the error
tangential measurement and allows true short-axis mea-
rement of aortic diameter. Essential element of aortic
aging reports are listed in Table 2.
.1. Chest X-Ray
outine chest x-ray may occasionally detect abnormalities
aortic contour or size that require definitive aortic
aging. Chest x-ray often serves as a part of the evalua-
on of patients with potential acute AoD, primarily to
entify other causes of patient’s symptoms, but also as a
reening test to identify findings due to a dilated aorta or
eeding.
.2. Computed Tomographic Imaging
T scanning has several advantages, including near-
iversal availability; the ability to image the entire aorta,
cluding lumen, wall, and periaortic regions; to identify
atomic variants and branch vessel involvement; to dis-
ble 4. Sex Differences in Aortic Root Dimensions in Adults
rtic Root
Absolute Values (cm)
Men p Value
nulus 2.60.3 0.001
nuses of Valsalva 3.40.3 0.001
notubular junction 2.90.3 0.001
oximal ascending aorta 3.00.4 0.001
NS indicates not significant. Adapted from Roman et al. (28).nguish among types of acute aortic syndromes (i.e., untramural hematoma [IMH], penetrating atherosclerotic
cer [PAU], and acute AoD); and the short time required
complete the imaging process and the 3-dimensional
ta. Electrocardiogram-gated techniques have made it
ssible to generate motion-free images of the aortic root
d coronary arteries, similar to coronary CT angiographic
aging. Reports of newer-generation multidetector heli-
l CT scanners show sensitivities of up to 100% and
ecificities of 98% to 99% (29 –32).
The sequence for a CT performed in the potential setting
acute AoD generally would include a noncontrast study
detect subtle changes of IMH, followed by a contrast
udy to delineate the presence and extent of the dissection
ap, identify regions of potential malperfusion, and dem-
strate contrast leak indicating rupture. Imaging of the
scular tree from the thoracic inlet to the pelvis, including
e iliac and femoral arteries, provides sufficient informa-
on to plan surgical or endovascular treatment, if needed.
rompt interpretation and communication of findings to
e appropriate treating physicians are essential in the
ute setting. (For further information on technique param-
ers and anatomic coverage, see the online-only data
pplement.)
.3. Magnetic Resonance Imaging
R has been shown to be very accurate in the diagnosis of
oracic aortic disease, with sensitivities and specificities
at are equivalent to or may exceed those of CT and
ansesophageal echocardiogram (TEE) (30,35–39). Ad-
ntages of MR include the ability to identify anatomic
riants of AoD (IMH and PAU), assess branch artery
volvement, and diagnose aortic valve pathology and left
ntricular dysfunction without exposing the patient to
ther radiation or iodinated contrast. Disadvantages in-
ude prolonged duration of imaging acquisition during
hich the patient is inaccessible to care providers; inabil-
y to use gadolinium contrast in patients with renal
sufficiency; contraindication in patients with claustro-
obia, metallic implants or pacemakers, and lack of
idespread availability on an emergency basis.
.4. Echocardiography
chocardiography can detect the presence of aortic enlarge-
ent and associated cardiac pathology that suggests the
Indexed Values (cm/m2)
omen Men p Value Women
30.2 1.30.1 NS 1.30.1
00.3 1.70.2 NS 1.80.2
60.3 1.50.2 NS 1.50.2
70.4 1.50.2 NS 1.60.3W
2.
3.
2.
2.derlying etiology of the aortic disease (e.g., bicuspid aortic
va
bo
fr
(F
re
si
th
se
Fi
flo
Fi
no
1518 Hiratzka et al. JACC Vol. 55, No. 14, 2010
2010 Guidelines on TAD: Executive Summary April 6, 2010:1509–44lve). For AoD (Figure 3), one of the major limitations of
th transthoracic echocardiogram (TTE) and TEE is the
equent appearance of artifacts that mimic a dissection flap
igure 4). These usually arise from a mirror image or
gure 3. Arch aneurysm with dissection flap. Panel A, Arch disse
w Doppler margination.
gure 4. Artifact mimicking dissection. Panel A, 2-dimensional vie
t seen in this view.verberation artifact that appears as a mobile linear echoden-
ty overlying the aortic lumen. It is therefore essential that
e echocardiographer make certain to distinguish true dis-
ction flaps from such artifacts.
-dimensional view. Panel B, Arch dissection (arrow) with color
el B, Color flow Doppler without margination. Panel C, Artifactction, 2w. Pan
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enetic Syndromes
ASS I
An echocardiogram is recommended at the time of diagnosis of
Marfan syndrome to determine the aortic root and ascending
aortic diameters (see Figure 5) and 6 months thereafter to
determine the rate of enlargement of the aorta. (Level of
Evidence: C)
Annual imaging is recommended for patients with Marfan
syndrome if stability of the aortic diameter is documented. If
the maximal aortic diameter is 4.5 cm or greater, or if the
aortic diameter shows significant growth from baseline, more
frequent imaging should be considered. (Level of Evidence: C)
Patients with Loeys-Dietz syndrome or a confirmed genetic
mutation known to predispose to aortic aneurysms and aortic
dissections (TGFBR1, TGFBR2, FBN1, ACTA2, or MYH11)
should undergo complete aortic imaging at initial diagnosis
and 6 months thereafter to establish if enlargement is occur-
ring (40–43). (Level of Evidence: C)
Patients with Loeys-Dietz syndrome should have yearly mag-
netic resonance imaging from the cerebrovascular circulation
to the pelvis (18,44,45). (Level of Evidence: B)
Patients with Turner syndrome should undergo imaging of the
heart and aorta for evidence of bicuspid aortic valve, coarcta-
tion of the aorta, or dilatation of the ascending thoracic aorta
(46). If initial imaging is normal and there are no risk factors
for aortic dissection, repeat imaging should be performed every
5 to 10 years or if otherwise clinically indicated. If abnormali-
ties exist, annual imaging or follow-up imaging should be done.
(Level of Evidence: C)
ASS IIa
It is reasonable to consider surgical repair of the aorta in all
adult patients with Loeys-Dietz syndrome or a confirmed TG-
FBR1 or TGFBR2 mutation and an aortic diameter of 4.2 cm or
greater by transesophageal echocardiogram (internal diame-
ter) or 4.4 to 4.6 cm or greater by computed tomographic
imaging and/or magnetic resonance imaging (external diame-
gure 5. Transthoracic echocardiogram of a patient with
arfan syndrome with mitral valve prolapse and 4-cm ascend-
g aortic aneurysm.ter) (44). (Level of Evidence: C)For women with Marfan syndrome contemplating pregnancy, it
is reasonable to prophylactically replace the aortic root and
ascending aorta if the diameter exceeds 4.0 cm (40). (Level of
Evidence: C)
If the maximal cross-sectional area in square centimeters of
the ascending aorta or root divided by the patient’s height in
meters exceeds a ratio of 10, surgical repair is reasonable
because shorter patients have dissection at a smaller size and
15% of patients with Marfan syndrome have dissection at a size
smaller than 5.0 cm (42,47,48). (Level of Evidence: C)
ASS IIb
In patients with Turner syndrome with additional risk factors,
including bicuspid aortic valve, coarctation of the aorta,
and/or hypertension, and in patients who attempt to become
pregnant or who become pregnant, it may be reasonable to
perform imaging of the heart and aorta to help determine the
risk of aortic dissection. (Level of Evidence: C)
here are several syndromic and nonsyndromic genetic
nditions that are associated with the development of
oracic aortic aneurysms and present with dissections at
aller diameters than usual. The following recommenda-
ons focus on these specific conditions, including Marfan
ndrome, Loeys-Dietz syndrome, Turner syndrome, bi-
spid aortic valve, and other genetic mutations (TGFBR1,
GFBR2, FBN1, ACTA2, COL3A1, MYH11) (see Tables 5
d 6).
A substantial proportion of Ehlers-Danlos syndrome pa-
nts who do not have the vascular form also have aortic root
latation but the progression of this dilatation to AoD is rare
2,49). Similarly, patients with congenital contractural
achnodactyly or Beals syndrome due to mutations in FBN2
ve had aortic root enlargement without documented pro-
ession to dissection (50,51).
There are other genetic syndromes that have multiple
ports or documentation of thoracic aortic aneurysms lead-
g to Type A dissections. There are multiple case reports of
oD in patients with autosomal dominant polycystic kidney
sease (52,53). Although AoD is a complication of autoso-
al dominant polycystic kidney disease, it is less common
an cerebral aneurysms leading to subarachnoid hemorrhage
this population. There is insufficient information to gauge
e value of routine or screening imaging for these patients.
Similar to autosomal dominant polycystic kidney disease,
ere are multiple reports in the literature of patients with
oonan syndrome experiencing AoDs (54–56). The value of
aging or routine monitoring of these patients is unknown. A
view of 200 patients with Alagille syndrome also identified
oracic aortic disease in a small subset of these patients (57).
. Recommendations for Familial
horacic Aortic Aneurysms and
issections
ASS I
Aortic imaging is recommended for first-degree relatives of
patients with thoracic aortic aneurysm and/or dissection to
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Evidence: B)
If the mutant gene (FBN1, TGFBR1, TGFBR2, COL3A1, ACTA2,
MYH11) associated with aortic aneurysm and/or dissection is
identified in a patient, first-degree relatives should undergo
counseling and testing. Then, only the relatives with the
genetic mutation should undergo aortic imaging. (Level of
Evidence: C)
ASS IIa
If one or more first-degree relatives of a patient with known
thoracic aortic aneurysm and/or dissection are found to have
ble 5. Gene Defects Associated With Familial Thoracic Aortic
fective Gene Leading to
milial Thoracic Aortic
eurysms and Dissection
Contribution to Familial
Thoracic Aortic Aneurysms
and Dissection
FBR2 mutations 4%
YH11 mutations 1%
TA2 mutations 14%
ACTA2 indicates actin, alpha 2, smooth muscle aorta; MYH11, smooth musc
ceptor type II.
ble 6. Genetic Syndromes Associated With Thoracic Aortic An
netic Syndrome Common Clinical Features Ge
arfan syndrome Skeletal features (see text) FBN
Ectopia lentis
Dural ectasia
eys-Dietz syndrome Bifid uvula or cleft palate TGFB
Arterial tortuosity
Hypertelorism
Skeletal features similar to MFS
Craniosynostosis
Aneurysms and dissections of other
arteries
lers-Danlos syndrome,
scular form
Thin, translucent skin COL3
Gastrointestinal rupture
Rupture of the gravid uterus
Rupture of medium-sized to large
arteries
rner syndrome Short stature 45
Primary amenorrhea
Bicuspid aortic valve
Aortic coarctation
Webbed neck, low-set ears, low hairline,
broad chest
AoD indicates aortic dissection; COL3A1, type III collagen; CT, computed tomo
aging; TEE, transesophageal echocardiogram; TGFBR1, transforming growth facto
*The defective gene at a second locus for MFS is TGFBR2 but the clinical phenotypethoracic aortic dilatation, aneurysm, or dissection, then imag-
ing of second-degree relatives is reasonable (58). (Level of
Evidence: B)
Sequencing of the ACTA2 gene is reasonable in patients with
a family history of thoracic aortic aneurysms and/or dissec-
tions to determine if ACTA2 mutations are responsible for the
inherited predisposition (13,14,43,44,60,61). (Level of Evi-
dence: B)
ASS IIb
Sequencing of other genes known to cause familial thoracic
aortic aneurysms and/or dissection (TGFBR1, TGFBR2,
sm and Dissection
Associated Clinical Features Comments on Aortic Disease
Thin, translucent skin
Arterial or aortic tortuosity
Aneurysm of arteries
Multiple aortic dissections
documented at aortic
diameters 5.0 cm
Patent ductus arteriosus Patient with documented
dissection at 4.5 cm
Livedo reticularis
Iris flocculi
Patent ductus arteriosus
Bicuspid aortic valve
Two of 13 patients with
documented dissections
5.0 cm
fic beta-myosin heavy chain; and TGFBR2, transforming growth factor-beta
and Dissection
fect Diagnostic Test Comments on Aortic Disease
ions* Ghent diagnostic criteria Surgical repair when the aorta
reaches 5.0 cm unless there
is a family history of AoD at
5.0 cm, a rapidly expanding
aneurysm or presence or
significant aortic valve
regurgitation
DNA for sequencing
GFBR1
s
DNA for sequencing Surgical repair recommended
at an aortic diameter of 4.2
cm by TEE (internal diameter)
or 4.4 to 4.6 cm by CT
and/or MR (external diameter)
ations DNA for sequencing Surgical repair is complicated
by friable tissues
Noninvasive imaging
recommended
Dermal fibroblasts for analysis
of type III collagen
type Blood (cells) for karyotype
analysis
AoD risk is increased in
patients with bicuspid aortic
valve, aortic coarctation,
hypertension, or pregnancy
imaging; FBN1, fibrillin 1; MFS, Marfan syndrome; MR, magnetic resonance
eceptor type I; and TGFBR2, transforming growth factor-beta receptor type II.Aneury
le specieurysm
netic De
1 mutat
R2 or T
mutation
A1 mut
,X karyo
graphic
r-beta ras MFS is debated.
2.
7
V
V
CL
1.
2.
8
A
Se
CL
1.
2.
3.
4.
CL
1.
9
P
D
CL
1.
Ta
Ao
Na
Ta
ar
Gi
ar
Be
dis
An
sp
1521JACC Vol. 55, No. 14, 2010 Hiratzka et al.
April 6, 2010:1509–44 2010 Guidelines on TAD: Executive SummaryMYH11) may be considered in patients with a family history
and clinical features associated with mutations in these genes
(13,14,43,44,60,61). (Level of Evidence: B)
If one or more first-degree relatives of a patient with known
thoracic aortic aneurysm and/or dissection are found to have
thoracic aortic dilatation, aneurysm, or dissection, then refer-
ral to a geneticist may be considered. (Level of Evidence: C)
. Recommendations for Bicuspid Aortic
alve and Associated Congenital
ariants in Adults
ASS I
First-degree relatives of patients with a bicuspid aortic valve,
premature onset of thoracic aortic disease with minimal risk
factors, and/or a familial form of thoracic aortic aneurysm and
dissection should be evaluated for the presence of a bicuspid
aortic valve and asymptomatic thoracic aortic disease. (Level
of Evidence: C)
All patients with a bicuspid aortic valve should have both the
aortic root and ascending thoracic aorta evaluated for evi-
dence of aortic dilatation (62–65). (Level of Evidence: B)
. Recommendations for Takayasu
rteritis and Giant Cell Arteritis
e Table 7 and Figure 6.
ASS I
Initial therapy for active Takayasu arteritis and active giant
cell arteritis should be corticosteroids at a high dose (pred-
nisone 40 to 60 mg daily at initiation or its equivalent) to
reduce the active inflammatory state (66,67). (Level of Evi-
dence: B)
The success of treatment of patients with Takayasu arteritis
and giant cell arteritis should be periodically evaluated to
determine disease activity by repeated physical examination
and either an erythrocyte sedimentation rate or C-reactive
protein level (68,69). (Level of Evidence: B)
Elective revascularization of patients with Takayasu arteritis
and giant cell arteritis should be delayed until the acute
inflammatory state is treated and quiescent (70). (Level of
Evidence: B)
The initial evaluation of Takayasu arteritis or giant cell arteritis
should include thoracic aorta and branch vessel computed
tomographic imaging or magnetic resonance imaging to inves-
tigate the possibility of aneurysm or occlusive disease in these
vessels. (Level of Evidence: C)
ASS IIa
It is reasonable to treat patients with Takayasu arteritis
receiving corticosteroids with an additional anti-
inflammatory agent if there is evidence of progression of
vascular disease, recurrence of constitutional symptoms, or
re-elevation of inflammatory marker (66). (Level of Evi-
dence: C). Recommendations for Estimation of
retest Risk of Thoracic Aortic
issection
ASS I
Providers should routinely evaluate any patient presenting with
complaints that may represent acute thoracic aortic dissection
to establish a pretest risk of disease that can then be used to
guide diagnostic decisions (see Figure 7). This process should
include specific questions about medical history, family his-
tory, and pain features as well as a focused examination to
identify findings that are associated with aortic dissection,
including:
a. High-risk conditions and historical features (see Table 8)
(59,75–77) (Level of Evidence: B):
• Marfan syndrome, Loeys-Dietz syndrome, vascular
Ehlers-Danlos syndrome, Turner syndrome, or other con-
nective tissue disease.
• Patients with mutations in genes known to predispose
to thoracic aortic aneurysms and dissection, such as
FBN1, TGFBR1, TGFBR2, ACTA2, and MYH11.
• Family history of aortic dissection or thoracic aortic
aneurysm.
• Known aortic valve disease.
• Recent aortic manipulation (surgical or catheter-based).
• Known thoracic aortic aneurysm.
b. High-risk chest, back or abdominal pain features (75–81)
(Level of Evidence: B):
ble 7. Inflammatory Diseases Associated With Thoracic
rtic Aneurysm and Dissection
mes Criteria Used in Diagnosis/Source
When Is Diagnosis
Established?
kayasu
teritis (71)
Age of onset 40 y
Intermittent claudication
Diminished brachial artery pulse
Subclavian artery or aortic bruit
Systolic BP variation of
10 mm Hg between arms
Aortographic evidence of aorta or
aortic branch stenosis
3 criteria are
present
(sensitivity 90.5%;
specificity 97.8%)
ant cell
teritis (72)
Age 50 y
Recent-onset localized headache
Temporary artery tenderness or
pulse attenuation
Elevated erythrocyte
sedimentation 50 mm/h
Arterial biopsy shows necrotizing
vasculitis
3 criteria are
present
(sensitivity 90%;
specificity 90%)
hçet
ease (73)
Oral ulceration
Recurrent genital ulceration
Uveitis or retinal vasculits
Skin lesions—erythema nodosum,
pseudo-folliculitis, or pathergy
Oral ulceration plus
2 of the other 3
criteria
kylosing
ondylitis (74)
Onset of pain 40 y
Back pain for 3 months
Morning stiffness
Subtle symptom onset
Improvement with exercise
4 of the diagnostic
criteria are present
BP indicates blood pressure.• Pain that is abrupt or instantaneous in onset.
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• Pain that has a ripping, tearing, stabbing, or sharp
quality.
c. High-risk examination features (75,77,81–84) (Level of
Evidence: B):
• Pulse deficit.
• Systolic blood pressure limb differential greater than 20
mm Hg.
• Focal neurological deficit.
• Murmur of aortic regurgitation (new).
Patients presenting with sudden onset of severe chest, back
and/or abdominal pain, particularly those less than 40 years of
age, should be questioned about a history and examined for
physical features of Marfan syndrome, Loeys-Dietz syndrome,
vascular Ehlers-Danlos syndrome, Turner syndrome, or other
connective tissue disorders associated with thoracic aortic
gure 6. Takayasu arteritis with involvement of the thoracoabdom
R examinations. Note narrowing of the arterial lumen and circum
oracic and abdominal aorta. Panel A, Image through the great ve
teries; Panel B, Mid descending thoracic aorta (arrowheads); Pan
l aorta; Panel E, Volume-rendered image from CT demonstrates
cic aorta; Panel G, Coronal MR of the abdominal aorta. CT indic
aging.disease (76). (Level of Evidence: B)Patients presenting with sudden onset of severe chest, back,
and/or abdominal pain should be questioned about a history of
aortic pathology in immediate family members as there is a
strong familial component to acute thoracic aortic disease
(76). (Level of Evidence: B)
Patients presenting with sudden onset of severe chest, back
and/or abdominal pain should be questioned about recent
aortic manipulation (surgical or catheter-based) or a known
history of aortic valvular disease, as these factors predispose
to acute aortic dissection. (Level of Evidence: C)
In patients with suspected or confirmed aortic dissection who
have experienced a syncopal episode, a focused examination
should be performed to identify associated neurological injury
or the presence of pericardial tamponade. (Level of Evidence: C)
All patients presenting with acute neurological complaints
should be questioned about the presence of chest, back,
rta and great vessels as shown on contrast-enhanced CT and
l soft tissue thickening of the walls of the great vessels and
ith narrowing of the left common carotid and left subclavian
orta just above the diaphragm (arrowheads); Panel D, Infrare-
tent of involvement; Panel F, Oblique sagittal MR of the tho-
mputed tomographic imaging; and MR, magnetic resonanceinal ao
ferentia
ssels w
el C, A
the ex
ates coand/or abdominal pain and checked for peripheral pulse defi-
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are less likely to report thoracic pain than the typical aortic
dissection patient (83). (Level of Evidence: C)
hese recommendations provide guidance to improve more
ompt diagnosis of acute AoD (Figure 7). The true incidence
acute AoD is difficult to define as AoD can be rapidly fatal
d when patients expire prior to hospitalization, death may
erroneously attributed to another cause. Acute AoD is
equently missed on initial presentation and early mortality
ong this group may be misclassified as nondissection
lated. Classes of intimal tears are described in Figure 8. The
gure 7. AoD evaluation pathway. ACS indicates acute coronary
rvous system; CT, computed tomographic imaging; CXR, chest
EMI, ST-elevated myocardial infarction; TAD; thoracic aortic diseBakey and Stanford Classifications of AoD are pictured ingure 9. There is no unanimity as to which classification
stem should be universally used.
0. Initial Evaluation and Management
f Acute Thoracic Aortic Disease
0.1. Recommendations for Screening Tests
ASS I
An electrocardiogram should be obtained on all patients who
present with symptoms that may represent acute thoracic
me; AoD, aortic dissection; BP, blood pressure; CNS, central
EKG, electrocardiogram; MR, magnetic resonance imaging;
nd TEE, transesophageal echocardiogram.syndro
x-ray;aortic dissection.
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nary artery occlusion, the presence of ST-segment eleva-
tion suggestive of myocardial infarction should be treated
as a primary cardiac event without delay for definitive
aortic imaging unless the patient is at high risk for aortic
dissection (75,81,88). (Level of Evidence: B)
The role of chest x-ray in the evaluation of possible thoracic
aortic disease should be directed by the patient’s pretest risk
of disease as follows:
a. Intermediate risk: Chest x-ray should be performed on all
intermediate-risk patients, as it may establish a clear
alternate diagnosis that will obviate the need for definitive
aortic imaging. (Level of Evidence: C)
b. Low risk: Chest x-ray should be performed on all low-risk
patients, as it may either establish an alternative diagnosis
or demonstrate findings that are suggestive of thoracic
aortic disease, indicating the need for urgent definitive
aortic imaging. (Level of Evidence: C)
Urgent and definitive imaging of the aorta using transesopha-
geal echocardiogram, computed tomographic imaging, or mag-
netic resonance imaging is recommended to identify or exclude
thoracic aortic dissection in patients at high risk for the
disease by initial screening (29–32,37,89,90). (Level of Evi-
dence: B)
ASS III
A negative chest x-ray should not delay definitive aortic imag-
ing in patients determined to be high risk for aortic dissection
ble 8. Risk Factors for Development of Thoracic Aortic
ssection
nditions associated with increased aortic wall stress
Hypertension, particularly if uncontrolled
Pheochromocytoma
Cocaine or other stimulant use
Weight lifting or other Valsalva maneuver
Trauma
Deceleration or torsional injury (e.g., motor vehicle crash, fall)
Coarctation of the aorta
nditions associated with aortic media abnormalities
Genetic
Marfan syndrome
Ehlers-Danlos syndrome, vascular form
Bicuspid aortic valve (including prior aortic valve replacement)
Turner syndrome
Loeys-Dietz syndrome
Familial thoracic aortic aneurysm and dissection syndrome
Inflammatory vasculitides
Takayasu arteritis
Giant cell arteritis
Behçet arteritis
Other
Pregnancy
Polycystic kidney disease
Chronic corticosteroid or immunosuppression agent administration
Infections involving the aortic wall either from bacteremia or extension of
adjacent infectionby initial screening. (Level of Evidence: C) Sv0.2. Recommendations for Diagnostic
aging Studies
ASS I
Selection of a specific imaging modality to identify or exclude
aortic dissection should be based on patient variables and
institutional capabilities, including immediate availability.
(Level of Evidence: C)
If a high clinical suspicion exists for acute aortic dissection but
initial aortic imaging is negative, a second imaging study
should be obtained. (85) (Level of Evidence: C)
0.3. Recommendations for Initial
anagement
e Figure 10.
ASS I
Initial management of thoracic aortic dissection should be
directed at decreasing aortic wall stress by controlling heart
rate and blood pressure as follows:
gure 8. Classes of intimal tears. I. Classic dissection with inti-
al tear and double lumen separated by septum. Communica-
n between lumens is typically in descending aorta at sheared-
f intercostal arteries or distal reentry site. II. IMH. No intimal
ar or septum is imaged but is usually found at surgery or au-
psy. DeBakey Types II and IIIa are common extent of this le-
on. III. Intimal tear without medial hematoma (limited dissec-
n) and eccentric aortic wall bulge. Rare and difficult to detect
TEE or CT. Patients with Marfan syndrome prone to this
pe. May result in aortic rupture or extravasation. IV. PAU usu-
ly to the adventitia with localized hematoma or saccular aneu-
sm. May propagate to Class I dissection, particularly when
volving ascending aorta or aortic arch. V. Iatrogenic (catheter
giography or intervention)/traumatic (deceleration) dissection.
T indicates computed tomographic imaging; IMH, intramural
matoma; PAU, penetrating atherosclerotic ulcer; and TEE,
nsesophegal echocardiography. Figure reprinted with permis-
on from the Cleveland Clinic Foundation. Legend adapted from
ensson et al. (85), Chirillo et al. (86), and Murray et al. (87).
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blockade should be initiated and titrated to a target heart
rate of 60 beats per minute or less. (Level of Evidence: C)
b. In patients with clear contraindications to beta blockade,
nondihydropyridine calcium channel–blocking agents
should be utilized as an alternative for rate control. (Level
of Evidence: C)
c. If systolic blood pressures remain greater than 120 mm Hg
after adequate heart rate control has been obtained, then
angiotensin-converting enzyme inhibitors and/or other va-
sodilators should be administered intravenously to further
reduce blood pressure that maintains adequate end-organ
perfusion. (Level of Evidence: C)
d. Beta blockers should be used cautiously in the setting of
acute aortic regurgitation because they will block the
compensatory tachycardia (4). (Level of Evidence: C)
ASS III
Vasodilator therapy should not be initiated prior to rate control
so as to avoid associated reflex tachycardia that may increase
aortic wall stress, leading to propagation or expansion of a
thoracic aortic dissection. (Level of Evidence: C)
0.4. Recommendations for Definitive
anagement
e Figures 9 and 11.
ASS I
Urgent surgical consultation should be obtained for all patients
diagnosed with thoracic aortic dissection regardless of the
anatomic location (ascending versus descending) as soon as
the diagnosis is made or highly suspected. (Level of Evidence: C)
Acute thoracic aortic dissection involving the ascending aorta
should be urgently evaluated for emergent surgical repair
because of the high risk of associated life-threatening compli-
cations such as rupture (75). (Level of Evidence: B)Acute thoracic aortic dissection involving the descending aorta
should be managed medically unless life-threatening complications
develop (e.g., malperfusion syndrome, progression of dissection,
enlarging aneurysm, inability to control blood pressure or symptoms)
(80,92–96). (Level of Evidence: B)
1. Recommendation for Surgical
tervention for Acute Thoracic Aortic
issection
ASS I
For patients with ascending thoracic aortic dissection, all
aneurysmal aorta and theproximal extent of thedissection should be
resected.Apartially dissectedaortic rootmaybe repairedwith aortic
valve resuspension. Extensive dissection of the aortic root should be
treated with aortic root replacement with a composite graft or with
a valve sparing root replacement. If a DeBakey Type II dissection is
present, the entire dissected aorta should be replaced. (Level of
Evidence: C)
2. Recommendation for Intramural
ematoma Without Intimal Defect
ASS IIa
It is reasonable to treat intramural hematoma similar to aortic
dissection in the corresponding segment of the aorta. (Level of
Evidence: C)
3. Recommendation for History and
hysical Examination for Thoracic Aortic
isease
ASS I
For patients presenting with a history of acute cardiac and
Figure 9. Aortic dissection classification:
DeBakey and Stanford classifications. Re-
printed with permission from the Cleveland
Clinic Foundation.noncardiac symptoms associated with a significant likeli-
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2010 Guidelines on TAD: Executive Summary April 6, 2010:1509–44hood of thoracic aortic disease, the clinician should perform
a focused physical examination, including a careful and
complete search for arterial perfusion differentials in both
upper and lower extremities, evidence of visceral ischemia,
focal neurological deficits, a murmur of aortic regurgitation,
bruits, and findings compatible with possible cardiac tam-
ponade (97–99). (Level of Evidence: C)
gure 10. Acute AoD management pathway. AoD indicates aortic
E, transthoracic echocardiogram.4. Recommendation for Medical
reatment of Patients With Thoracic
ortic Diseases
ASS I
Stringent control of hypertension, lipid profile optimization,
smoking cessation, and other atherosclerosis risk-reduction
tion; BP, blood pressure; MAP, mean arterial pressure; anddissec
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rysms not requiring surgery, as well as for patients who are not
considered surgical or stent graft candidates (see Table 9).
(Level of Evidence: C)
4.1. Recommendations for Blood Pressure
ontrol
ASS I
Antihypertensive therapy should be administered to hyperten-
sive patients with thoracic aortic diseases to achieve a goal of
less than 140/90 mm Hg (patients without diabetes) or less
than 130/80 mm Hg (patients with diabetes or chronic renal
disease) to reduce the risk of stroke, myocardial infarction,
heart failure, and cardiovascular death (107–111). (Level of
Evidence: B)Beta adrenergic–blocking drugs should be administered to all
patients with Marfan syndrome and aortic aneurysm to reduce
the rate of aortic dilatation unless contraindicated (101).
(Level of Evidence: B)
ASS IIa
For patients with thoracic aortic aneurysm, it is reasonable to
reduce blood pressure with beta blockers and angiotensin-
converting enzyme inhibitors (103) or angiotensin receptor
blockers (104,105) to the lowest point patients can tolerate
without adverse effects (100–102). (Level of Evidence: B)
An angiotensin receptor blocker (losartan) is reasonable for
patients with Marfan syndrome, to reduce the rate of aortic
dilatation unless contraindicated (105,112). (Level of Evi-
Figure 11. Acute surgical management
pathway for AoD. AoD indicates aortic dis-
section; CABG, coronary artery bypass
graft surgery; CAD, coronary artery dis-
ease; TAD, thoracic aortic disease; and
TEE, transesophageal echocardiogram.
*Addition of ‘if appropriate’ based on Patel
et al. (96a).dence: B)
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ASS IIa
Treatment with a statin to achieve a target LDL cholesterol of
less than 70 mg/dL is reasonable for patients with a coronary
heart disease risk equivalent such as noncoronary atheroscle-
rotic disease, atherosclerotic aortic aneurysm, and coexistent
coronary heart disease at high risk for coronary ischemic
events (113–116). (Level of Evidence: A)
4.3. Recommendation for Smoking
essation
ASS I
Smoking cessation and avoidance of exposure to environmen-
tal tobacco smoke at work and home are recommended.
Follow-up, referral to special programs, and/or pharmacother-
apy (including nicotine replacement, buproprion, or vareni-
ble 9. Studies of Medical Treatment of Thoracic Aortic Aneury
eatment Studies
ta blockers Genoni M, Paul M, Jenni R,
et al. (100)
Retro
rece
treat
patie
surg
the b
Shores J, Berger KR,
Murphy EA, et al. (101)
Open
synd
d. Pr
Ladouceur M, Fermanian C,
Lupoglazoff JM, et al. (102)
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giotensin-converting
zyme inhibitors
Ahimastos AA, Aggarwal A,
D’Orsa KM, et al. (103)
Rand
synd
thera
smal
p0
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giotensin receptor
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Mochizuki S, Dahlof B,
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AAA indicates abdominal aortic aneurysm; CI, confidence interval; SD, standacline) is useful, as is adopting a stepwise strategy aimed atsmoking cessation (the 5 As are Ask, Advise, Assess, Assist,
and Arrange) (117–118b ). (Level of Evidence: B)
5. Recommendations for Asymptomatic
atients With Ascending Aortic
neurysm
e Figures 12 and 13.
ASS I
Asymptomatic patients with degenerative thoracic aneurysm,
chronic aortic dissection, intramural hematoma, penetrating
atherosclerotic ulcer, mycotic aneurysm, or pseudoaneurysm,
who are otherwise suitable candidates and for whom the
ascending aorta or aortic sinus diameter is 5.5 cm or greater
should be evaluated for surgical repair (119). (Level of Evi-
dence: C)
Results
, case-record review of 78 patients with chronic Type B dissection who
dical treatment. 51 of 71 received beta-blocker treatment, 20 of 71 were
other antihypertensive drugs. 10 of 51 (20%) of the beta-blocker–treated
9 of 20 (45%) from the other treatment group needed dissection-related
0.002). The incidence of increasing aortic diameter was 12% (6 of 51) in
ker group and 40% (8 of 20) in the other treatment group (p0.002).
randomized, control study of propranolol in 70 patients with Marfan
he treated group received a mean daily propranolol dose of 21268 mg/
l therapy slowed aortic root dilation (0.023 vs 0.084 per year, p0.001).
evaluation of aortic dilation in children with Marfan syndrome. Aortic
s slowed by 0.2 mm/y in children treated with beta blockers.
double-blind, placebo-controlled trial of 17 patients with Marfan
king beta-blocker therapy to perindopril or placebo. After 24 weeks of
perindopril-treated subjects compared with placebo-treated subjects had
th in the ascending aortic diameter during systole (1.2 vs 0.3 mm/m2,
a significant reduction in ascending aortic diameter during diastole (0.4
/m2, p0.001), respectively.
se patients with hypertension, coronary heart disease, heart failure, or a
were randomly assigned either to open-label valsartan (40 to 160 mg/d)
reatment without angiotension receptor blockers. Patients randomized to
d reduction in composite cardiovascular outcome (OR 0.61, 95% CI 0.47
reduction in aortic dissection (OR 0.18, 95% CI 0.04 to 0.88). Open-label,
response to angiotension receptor blockers (losartan in 17 patients and
1 patient) were evaluated in pediatric patients with Marfan syndrome
aortic root enlargement. The mean (SD) rate of change in aortic root
reased significantly from 3.542.87 mm/y during previous medical
.460.62 mm/y during angiotension receptor blocker therapy (p0.001).
of aortic root enlargement from normal, as expressed by the rate of
scores, was reduced by a mean difference of 1.47 z scores/y (95% CI
, p0.001) after the initiation of angiotension receptor blocker therapy.
lar junction showed a reduced rate of change in diameter during
receptor blocker therapy (p0.05), whereas the distal ascending aorta
cted by angiotension receptor blocker therapy.
ized propensity-score–adjusted study of statin use effect on long-term
patients after endovascular repair of AAA (731 patients) or TAA (59
s done. Statin use was associated with decreased long-term mortality in
AAA (adjusted HR 0.613, 95% CI 0.379 to 0.993, p0.047), but not for
TAA (adjusted HR 1.795, 95% CI 0.147 to 21.942, p0.647).
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April 6, 2010:1509–44 2010 Guidelines on TAD: Executive SummaryPatients with Marfan syndrome or other genetically mediated
disorders (vascular Ehlers-Danlos syndrome, Turner syndrome,
bicuspid aortic valve, or familial thoracic aortic aneurysm and
dissection) should undergo elective operation at smaller diam-
eters (4.0 to 5.0 cm depending on the condition; see Section
5) to avoid acute dissection or rupture (47,119–125). (Level of
Evidence: C)
Patients with a growth rate of more than 0.5 cm/y in an aorta
that is less than 5.5 cm in diameter should be considered for
operation. (Level of Evidence: C)
Patients undergoing aortic valve repair or replacement and who
have an ascending aorta or aortic root of greater than 4.5 cm
should be considered for concomitant repair of the aortic root
or replacement of the ascending aorta. (Level of Evidence: C)
ASS IIa
Elective aortic replacement is reasonable for patients with
Marfan syndrome, other genetic diseases, or bicuspid aorticvalves, when the ratio of maximal ascending or aortic root area
(r2) in cm2 divided by the patient’s height in meters exceeds
10 (48,123). (Level of Evidence: C)
It is reasonable for patients with Loeys-Dietz syndrome or a
confirmed TGFBR1 or TGFBR2 mutation to undergo aortic
repair when the aortic diameter reaches 4.2 cm or greater by
transesophageal echocardiogram (internal diameter) or 4.4 to
4.6 cm or greater by computed tomographic imaging and/or
magnetic resonance imaging (external diameter) (44). (Level
of Evidence: C)
6. Recommendation for Symptomatic
atients With Thoracic Aortic Aneurysm
ASS I
Patients with symptoms suggestive of expansion of a tho-
Figure 12. Ascending aortic aneurysm of
degenerative etiology. CABG indicates cor-
onary artery bypass graft surgery; CAD,
coronary artery disease; CT, computed to-
mographic imaging; and MR, magnetic res-
onance imaging.racic aneurysm should be evaluated for prompt surgical inter-
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limited or quality of life is substantially impaired. (Level of
Evidence: C)
7. Recommendations for Open Surgery
r Ascending Aortic Aneurysm
ASS I
Separate valve and ascending aortic replacement are recom-
mended in patients without significant aortic root dilatation, in
elderly patients, or in young patients with minimal dilatation
who have aortic valve disease. (Level of Evidence: C)
Patients with Marfan, Loeys-Dietz, and Ehlers-Danlos syn-
dromes and other patients with dilatation of the aortic root and
sinuses of Valsalva should undergo excision of the sinuses in
combination with a modified David reimplantation operation if
technically feasible or, if not, root replacement with valved
graft conduit (72,126–129). (Level of Evidence: B)8. Recommendations for Aortic Arch
neurysms
ASS IIa
For thoracic aortic aneurysms also involving the proximal
aortic arch, partial arch replacement together with ascending
aorta repair using right subclavian/axillary artery inflow and
hypothermic circulatory arrest is reasonable (130–132). (Level
of Evidence: B)
Replacement of the entire aortic arch is reasonable for acute
dissection when the arch is aneurysmal or there is extensive
aortic arch destruction and leakage (131,132). (Level of
Evidence: B)
Replacement of the entire aortic arch is reasonable for aneu-
rysms of the entire arch, for chronic dissection when the arch
is enlarged, and for distal arch aneurysms that also involve the
Figure 13. Ascending aortic aneurysms
associated with genetic disorder. CABG
indicates coronary artery bypass graft sur-
gery; CAD, coronary artery disease; CT,
computed tomographic imaging; and MR,
magnetic resonance imaging. *Depends
on specific genetic condition. †See Rec-
ommendations for Asymptomatic Patients
With Ascending Aortic Aneurysm (Section
15), and Recommendations for Bicuspid
Aortic Valve and Associated Congenital
Variants in Adults (Section 7).proximal descending thoracic aorta, usually with the elephant
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dence: B)
For patients with low operative risk in whom an isolated
degenerative or atherosclerotic aneurysm of the aortic arch is
present, operative treatment is reasonable for asymptomatic
patients when the diameter of the arch exceeds 5.5 cm (136).
(Level of Evidence: B)
For patients with isolated aortic arch aneurysms less than 4.0
cm in diameter, it is reasonable to reimage using computed
tomographic imaging or magnetic resonance imaging, at 12-
month intervals, to detect enlargement of the aneurysm. (Level
of Evidence: C)
For patients with isolated aortic arch aneurysms 4.0 cm or
greater in diameter, it is reasonable to reimage using com-
puted tomographic imaging or magnetic resonance imaging, at
6-month intervals, to detect enlargement of the aneurysm.
(Level of Evidence: C)
9. Recommendations for Descending
horacic Aorta and Thoracoabdominal
ortic Aneurysms
ASS I
For patients with chronic dissection, particularly if associated
with a connective tissue disorder, but without significant
comorbid disease, and a descending thoracic aortic diameter
exceeding 5.5 cm, open repair is recommended
(119,137,138). (Level of Evidence: B)
For patients with degenerative or traumatic aneurysms of the
descending thoracic aorta exceeding 5.5 cm, saccular aneu-
rysms, or postoperative pseudoaneurysms, endovascular stent
grafting should be strongly considered when feasible
(119,139) (see Table 10). (Level of Evidence: B)For patients with thoracoabdominal aneurysms, in whom endo-
vascular stent graft options are limited and surgical morbidity
is elevated, elective surgery is recommended if the aortic
diameter exceeds 6.0 cm, or less if a connective tissue
disorder such as Marfan or Loeys-Dietz syndrome is present
(119). (Level of Evidence: C)
Figure 14. Elephant trunk procedure. Panel
A, Preoperative disease. Panel B, Stage I
with replacement of the ascending aorta
and arch with a Dacron graft, with the dis-
tal graft sutured circumferentially to the
aorta distal to the left subclavian artery and
the free end of the graft (“elephant trunk”)
within the descending aneurysm. Panel C,
Completion of the procedure using an en-
dovascular stent graft attached proximally
to the “elephant trunk” and the distal end
secured to a Dacron graft cuff. Images re-
printed with permission from the Cleveland
Clinic Foundation.
ble 10. Summary of Society of Thoracic Surgeons
commendations for Thoracic Stent Graft Insertion
tity/Subgroup Classification
Level of
Evidence
netrating ulcer/intramural hematoma
Asymptomatic III C
Symptomatic IIa C
ute traumatic I B
ronic traumatic IIa C
ute Type B dissection
Ischemia I A
No ischemia IIb C
bacute dissection IIb B
ronic dissection IIb B
generative descending
5.5 cm, comorbidity IIa B
5.5 cm, no comorbidity IIb C
5.5 cm III C
ch
Reasonable open risk III A
Severe comorbidity IIb C
oracoabdominal/Severe comorbidity IIb CReprinted from Svensson et al. (119).
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organ ischemia or significant stenosis from atherosclerotic
visceral artery disease, an additional revascularization proce-
dure is recommended (140). (Level of Evidence: B)
0. Recommendations for Counseling
nd Management of Chronic Aortic
iseases in Pregnancy
ASS I
Women with Marfan syndrome and aortic dilatation, as well as
patients without Marfan syndrome who have known aortic
disease, should be counseled about the risk of aortic dissec-
tion as well as the heritable nature of the disease prior to
pregnancy (40,141). (Level of Evidence: C)
For pregnant women with known thoracic aortic dilatation or a
familial or genetic predisposition for aortic dissection, strict
blood pressure control, specifically to prevent Stage II hyper-
tension, is recommended. (Level of Evidence: C)
For all pregnant women with known aortic root or ascending
aortic dilatation, monthly or bimonthly echocardiographic mea-
surements of the ascending aortic dimensions are recom-
mended to detect aortic expansion until birth. (Level of Evi-
dence: C)
For imaging of pregnant women with aortic arch, descending,
or abdominal aortic dilatation, magnetic resonance imaging
(without gadolinium) is recommended over computed tomo-
graphic imaging to avoid exposing both the mother and fetus to
ionizing radiation. Transesophageal echocardiogram is an op-
tion for imaging of the thoracic aorta. (Level of Evidence: C)
Pregnant women with aortic aneurysms should be delivered
where cardiothoracic surgery is available. (Level of Evi-
dence: C)
ASS IIa
Fetal delivery via cesarean section is reasonable for patients
with significant aortic enlargement, dissection, or severe aor-
tic valve regurgitation (141). (Level of Evidence: C)
ASS IIb
If progressive aortic dilatation and/or advancing aortic valve
regurgitation are documented, prophylactic surgery may be
considered (142). (Level of Evidence: C)
1. Recommendations for Aortic Arch
nd Thoracic Aortic Atheroma and
theroembolic Disease
ASS IIa
Treatment with a statin is a reasonable option for patients with
aortic arch atheroma to reduce the risk of stroke (143). (Level
of Evidence: C)
ASS IIb
Oral anticoagulation therapy with warfarin (INR, 2.0 to 3.0) or
antiplatelet therapy may be considered in stroke patients with
aortic arch atheroma 4.0 mm or greater to prevent recurrent
stroke. (Level of Evidence: C)2. Periprocedural and Perioperative
anagement
ctions 22.1 to 22.6 list recommendations regarding the
riprocedural and perioperative management of patients under-
ing open surgical or thoracic aortic endograft procedures
cluding strategies to preserve end-organ function. More de-
iled discussions are available in the full-text document.
2.1. Recommendations for Preoperative
valuation
ASS I
In preparation for surgery, imaging studies adequate to estab-
lish the extent of disease and the potential limits of the
planned procedure are recommended. (Level of Evidence: C)
Patients with thoracic aortic disease requiring a surgical or
catheter-based intervention who have symptoms or other find-
ings of myocardial ischemia should undergo additional studies
to determine the presence of significant coronary artery dis-
ease. (Level of Evidence: C)
Patients with unstable coronary syndromes and significant coro-
nary artery disease should undergo revascularization prior to or at
the time of thoracic aortic surgery or endovascular intervention
with percutaneous coronary intervention or concomitant coronary
artery bypass graft surgery. (Level of Evidence: C)
ASS IIa
Additional testing is reasonable to quantitate the patient’s
comorbid states and develop a risk profile. These may include
pulmonary function tests, cardiac catheterization, aortogra-
phy, 24-hour Holter monitoring, noninvasive carotid artery
screening, brain imaging, echocardiography, and neurocogni-
tive testing. (Level of Evidence: C)
For patients who are to undergo surgery for ascending or arch
aortic disease, and who have clinically stable, but significant
(flow limiting), coronary artery disease, it is reasonable to
perform concomitant coronary artery bypass graft surgery.
(Level of Evidence: C)
ASS IIb
For patients who are to undergo surgery or endovascular
intervention for descending thoracic aortic disease, and who
have clinically stable, but significant (flow limiting), coronary
artery disease, the benefits of coronary revascularization are
not well established (144–146). (Level of Evidence: B)
2.2. Recommendations for Choice of
nesthetic and Monitoring Techniques
ASS I
The choice of anesthetic techniques and agents and patient
monitoring techniques should be tailored to individual patient
needs to facilitate surgical and perfusion techniques and the
monitoring of hemodynamics and organ function. (Level of Evi-
dence: C)
ASS IIa
Transesophageal echocardiography is reasonable in all open
surgical repairs of the thoracic aorta, unless there are specific
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phy is reasonable in endovascular thoracic aortic procedures
for monitoring, procedural guidance, and/or endovascular graft
leak detection (147–149). (Level of Evidence: B)
Motor or somatosensory evoked potential monitoring can be
useful when the data will help to guide therapy. It is reasonable
to base the decision to use neurophysiologic monitoring on
individual patient needs, institutional resources, the urgency of
the procedure, and the surgical and perfusion techniques to be
employed in the open or endovascular thoracic aortic repair
(150,151). (Level of Evidence: B)
ASS III
Regional anesthetic techniques are not recommended in pa-
tients at risk of neuraxial hematoma formation due to thien-
opyridine antiplatelet therapy, low-molecular-weight heparins,
or clinically significant anticoagulation (152). (Level of Evi-
dence: C)
Routinely changing double-lumen endotracheal (endobron-
chial) tubes to single-lumen tubes at the end of surgical
procedures complicated by significant upper airway edema or
hemorrhage is not recommended. (Level of Evidence: C)
2.3. Recommendation for Transfusion
anagement and Anticoagulation in Thoracic
ortic Surgery
ASS IIa
An algorithmic approach to transfusion, antifibrinolytic, and
anticoagulation management is reasonable to use in both open
and endovascular thoracic aortic repairs during the periopera-
tive period. Institutional variations in coagulation testing ca-
pability and availability of transfusion products and other
prothrombotic and antithrombotic agents are important consid-
erations in defining such an approach (153). (Level of Evi-
dence: C)
2.4. Recommendations for Brain Protection
uring Ascending Aortic and Transverse
ortic Arch Surgery
ASS I
A brain protection strategy to prevent stroke and preserve
cognitive function should be a key element of the surgical,
anesthetic, and perfusion techniques used to accomplish re-
pairs of the ascending aorta and transverse aortic arch
(154–160). (Level of Evidence: B)
ASS IIa
Deep hypothermic circulatory arrest, selective antegrade brain
perfusion, and retrograde brain perfusion are techniques that
alone or in combination are reasonable to minimize brain injury
during surgical repairs of the ascending aorta and transverse
aortic arch. Institutional experience is an important factor in
selecting these techniques (161–184). (Level of Evidence: B)
ASS III
Perioperative brain hyperthermia is not recommended in repairs of
the ascending aortic and transverse aortic arch as it is probably
injurious to the brain (185–187). (Level of Evidence: B)2.5. Recommendations for Spinal Cord
rotection During Descending Aortic Open
urgical and Endovascular Repairs
ASS I
Cerebrospinal fluid drainage is recommended as a spinal cord
protective strategy in open and endovascular thoracic aortic
repair for patients at high risk of spinal cord ischemic injury
(188–190). (Level of Evidence: B)
ASS IIa
Spinal cord perfusion pressure optimization using techniques,
such as proximal aortic pressure maintenance and distal aortic
perfusion, is reasonable as an integral part of the surgical,
anesthetic, and perfusion strategy in open and endovascular
thoracic aortic repair patients at high risk of spinal cord
ischemic injury. Institutional experience is an important factor
in selecting these techniques (138,191–193). (Level of Evi-
dence: B)
Moderate systemic hypothermia is reasonable for protection of
the spinal cord during open repairs of the descending thoracic
aorta (194). (Level of Evidence: B)
ASS IIb
Adjunctive techniques to increase the tolerance of the spinal cord
to impaired perfusion may be considered during open and
endovascular thoracic aortic repair for patients at high risk
of spinal cord injury. These include distal perfusion, epidural
irrigation with hypothermic solutions, high-dose systemic
glucocorticoids, osmotic diuresis with mannitol, intrathecal
papaverine, and cellular metabolic suppression with anes-
thetic agents (193,195–197). (Level of Evidence: B)
Neurophysiological monitoring of the spinal cord (somatosen-
sory evoked potentials or motor evoked potentials) may be
considered as a strategy to detect spinal cord ischemia and to
guide reimplantation of intercostal arteries and/or hemody-
namic optimization to prevent or treat spinal cord ischemia
(150,198–200). (Level of Evidence: B)
2.6. Recommendations for Renal Protection
uring Descending Aortic Open Surgical and
ndovascular Repairs
ASS IIb
Preoperative hydration and intraoperative mannitol administra-
tion may be reasonable strategies for preservation of renal
function in open repairs of the descending aorta. (Level of
Evidence: C)
During thoracoabdominal or descending aortic repairs with
exposure of the renal arteries, renal protection by either cold
crystalloid or blood perfusion may be considered (201–203).
(Level of Evidence: B)
ASS III
Furosemide, mannitol, or dopamine should not be given solely
for the purpose of renal protection in descending aortic repairs
(204,205). (Level of Evidence: B)
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f Thoracic Aortic Disease or Previously
epaired Patients
ASS IIa
Computed tomographic imaging or magnetic resonance imag-
ing of the thoracic aorta is reasonable after a Type A or B aortic
dissection or after prophylactic repair of the aortic root/
ascending aorta (40). (Level of Evidence: C)
Computed tomographic imaging or magnetic resonance imag-
ing of the aorta is reasonable at 1, 3, 6, and 12 months
postdissection and, if stable, annually thereafter so that any
threatening enlargement can be detected in a timely fashion.
(Level of Evidence: C)
When following patients with imaging, utilization of the same
modality at the same institution is reasonable, so that similar
images of matching anatomic segments can be compared side
by side. (Level of Evidence: C)
If a thoracic aortic aneurysm is only moderate in size and remains
relatively stable over time, magnetic resonance imaging instead
of computed tomographic imaging is reasonable to minimize the
patient’s radiation exposure. (Level of Evidence: C)
Surveillance imaging similar to classic aortic dissection is
reasonable in patients with intramural hematoma. (Level of
Evidence: C)
he mean rate of growth for all thoracic aortic aneurysms is
proximately 1 mm/y, but that growth rate increases with
creasing aneurysm diameter. Growth rates tend to be faster
r aneurysms involving the descending versus the ascending
rta, for dissected versus nondissected aortas, for those with
arfan syndrome versus those without (206), and for those
ith bicuspid versus tricuspid aortic valves (207). Table 11
tes suggested intervals for follow up.
4. Recommendation for Employment
nd Lifestyle in Patients With Thoracic
ortic Disease
ASS IIa
For patients with a current thoracic aortic aneurysm or dissec-
tion, or previously repaired aortic dissection, employment and
lifestyle restrictions are reasonable, including the avoidance of
strenuous lifting, pushing or straining that would require a
Valsalva maneuver. (Level of Evidence: C)
stablishing clear lifestyle goals for patients with thoracic
rtic disease is important in improving long-term health and
ducing the risk of complications.
There are no outcomes data, and scant data of any
riety for that matter, to indicate how much exercise is
fe or beneficial for patients with thoracic aortic disease.
owever, aerobic exercise, sometimes referred to as dy-
mic exercise, is associated with only a modest increase
mean arterial pressure (209), and AoD rarely occurs
ring aerobic exercise. Consequently, most experts be-
eve that aerobic exercise, particularly when heart rate and
ood pressure are well controlled with medications, is
neficial overall. Nevertheless, if patients wish to engage revigorous aerobic exercise, such as running or basketball,
e might consider performing a symptom limited stress
st to ensure that the patient does not have a hypertensive
sponse to exercise.
Conversely, with isometric exercise, there is a significant
crease in mean arterial pressure. When the Valsalva ma-
uver is used for the lifting of heavy weights, there is a
perimposed increase in intrathoracic pressure, followed by
dramatic increase in systemic arterial pressure (209), with
stolic pressures reaching 300 mm Hg or more (210). As a
sult, most experts believe that heavy weight lifting or
mpetitive athletics involving isometric exercise may trigger
oD and/or rupture and that such activities should be avoided
11). Working with patients on an individualized basis to
reamline these goals based on insufficient data can be
allenging. For patients who are very much interested in
aintaining some sort of weight lifting program, choosing
ts of repetitive light weights appears to make more sense
an permitting heavy weight lifting (209).
5. Tumors of the Thoracic Aorta
eoplasms of the thoracic aorta are usually secondary and
lated to contiguous spread of adjacent primary malignan-
es, particularly lung and adjacent primary malignancies or
bsequent metastases, particularly lung and esophagus
12–215). Primary neoplasms of the thoracic aorta are rare
13). Metastatic disease is often demonstrated at the time of
agnosis of primary aortic neoplasms. Symptoms may in-
ude malaise, fatigue, weight loss and nausea or the occur-
ble 11. Suggested Follow-Up of Aortic Pathologies After
pair or Treatment
thology Interval Study
ute
section
Before discharge, 1 month, 6
months, yearly
CT or MR, chest plus
abdomen TTE
ronic
section
Before discharge, 1 y, 2 to 3 y CT or MR, chest plus
abdomen TTE
rtic root
pair
Before discharge, yearly TTE
R plus
cending
Before discharge, yearly TTE
rtic arch Before discharge, 1 y, 2 to 3 y CT or MR, chest plus
abdomen
oracic aortic
nt
Before discharge, 1 month, 2
months, 6 months, yearly Or
30 days*
CXR, CT, chest plus
abdomen
ute IMH/PAU Before discharge, 1 month, 3
months, 6 months, yearly
CT or MR, chest plus
abdomen
AVR indicates aortic valve replacement; CT, computed tomographic imaging;
R, chest x-ray; IMH, intramural hematoma; MR, magnetic resonance
aging; PAU, penetrating atherosclerotic ulcer; and TTE, transthoracic
hocardiography.
*US Food and Drug Administration stent graft studies usually required before
charge or at 30-day CT scan to detect endovascular leaks. If there is
ncern about a leak, a predischarge study is recommended; however, the risk
renal injury should be borne in mind. All patients should be receiving beta
ckers after surgery or medically managed aortic dissection, if tolerated.
apted from Erbel et al. (208).nce of distal arterial embolization (with histopathologic
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chniques during a search for an embolic source) (216–218).
oD may originate in the area of the neoplasm or the aortic
clusion (219). Resection and reconstruction of the segment
aorta containing the neoplasm have been described, but
cause most patients present with metastatic disease, overall
ognosis is poor (220).
6. Recommendations for Quality
ssessment and Improvement for
horacic Aortic Disease
ASS I
Hospitals that provide regional care for patients with acute
sequelae of thoracic aortic disease (e.g., procedures for tho-
racic aortic dissection and rupture) should participate in
standardized quality assessment and improvement activities,
including thoracic aortic disease registries. Such activities
should include periodic measurement and regional/national
interfacility comparisons of thoracic aortic disease-related
procedural volumes, complications and risk-adjusted mortality
rates. (Level of Evidence: C)
Hospitals that provide regional care for patients with acute
sequelae of thoracic aortic disease (e.g., procedures for tho-
racic aortic dissection and rupture) should facilitate and
coordinate standardized quality assessment and improvement
activities with transferring facilities and emergency medical
services teams. Such activities might include:
a. cooperative joint facility meetings to discuss opportunities
for quality improvement and
b. interfacility and emergency medical services team compar-
isons of pretransfer care based on available outcome data
and future performance measures developed in accordance
with this guideline. (Level of Evidence: C)
tients with acute aortic syndromes may require transfer to
ecialized institutions. Ideally, the communications between
stitutions will completely and accurately portray the condi-
n of the patient including items listed in Table 12.taff
merican College of Cardiology Foundation
hn C. Lewin, MD, Chief Executive Officer
harlene May, Senior Director, Science and Clinical Policy
isa Bradfield, CAE, Associate Director, Science and Clini-
cal Policy
ark D. Stewart, MPH, Associate Director, Evidence-Based
Medicine
e Keller, BSN, MPH, Senior Specialist, Evidence-Based
Medicine
rin A. Barrett, Senior Specialist, Science and Clinical Policy
sse M. Welsh, Specialist, Science and Clinical Policy
merican Heart Association
ancy Brown, Chief Executive Officer
ayle R. Whitman, PhD, RN, FAHA, FAAN, Senior Vice
ble 12. Standardized Transferring Facility Assessment,
mmunication, and Documentation for the Following Domains
Blood pressure control for hypertension
Heart rate control for tachycardia
Hemodynamic instability
Blood volume
Cardiac ischemia
Neurologic ischemia
Renal function
Mesenteric ischemia
Peripheral arterial pulses and perfusion
Activation of receiving team
Imaging expectations and communications
Timeliness and efficiency
EMS characteristics of transferring facility, including requisite personnel,
requisite in-transport equipment, including catastrophic resuscitation
capabilities, in-transfer contingency planning, weather conditions,
estimated transfer time, etc.
EMS indicates emergency medical services.President, Office of Science Operations
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